Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy
- PMID: 33632798
- DOI: 10.1183/13993003.00166-2021
Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy
Conflict of interest statement
Conflict of interest: A.P. Hearn has nothing to disclose. Conflict of interest: O.D. Hug has nothing to disclose. Conflict of interest: Z.A. Somani has nothing to disclose. Conflict of interest: J. Kavanagh reports other (travel support for meetings) from Teva, outside the submitted work. Conflict of interest: G. d'Ancona reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work. Conflict of interest: C. Roxas has nothing to disclose. Conflict of interest: L. Green has nothing to disclose. Conflict of interest: L. Thomson has nothing to disclose. Conflict of interest: M. Fernandes has nothing to disclose. Conflict of interest: B.D. Kent reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work. Conflict of interest: J. Dhariwal reports other (travel support for meetings) from Sanofi, outside the submitted work. Conflict of interest: A.M. Nanzer reports other (travel support for meetings) from Napp, and personal fees for lectures from AstraZeneca, outside the submitted work. Conflict of interest: D.J. Jackson reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources